Ongoing, recruitingTherapeutic use (Phase IV)Interventional

Evolution of proteinuria in renal transplant patients treated with Dapagliflozin for nephroprotection. DAPAGREFFE

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic use (Phase IV)

Sponsor

Centre Hospitalier Universitaire De Montpellier

Enrolment target

Start

13 Oct 2023

chronic renal failure

What is this study about?

Decrease in albuminuria/creatinuria ratio ≥ 50% from baseline or achievement of albuminuria/creatinuria ratio ≤ 30 mg/g at 6 months after introduction of dapagliflozin

Who may be eligible?

Age 18 Years to any · Sex: All

Locations (1)

—
France

How to find out more

Official trial record

Always speak to your GP or specialist before deciding to take part in a study.